Metástasis

European Medicines Agency Validates Marketing Authorization Application for Sacituzumab Govitecan-Hziy for the Treatment of Metastatic Triple-Negative Breast Cancer

Retrieved on: 
Thursday, March 25, 2021
Oncology, Health, FDA, Hospitals, Clinical trials, Pharmaceutical, Biotechnology, Breast cancer, Clinical medicine, Cancer, Triple-negative breast cancer, Metastatic breast cancer, Metástasis, Bemcentinib, Pembrolizumab

Metastatic triple-negative breast cancer is an aggressive and life-threatening cancer.

Key Points: 
  • Metastatic triple-negative breast cancer is an aggressive and life-threatening cancer.
  • The validation of our EU marketing application is an important step toward addressing the significant unmet medical need for people with metastatic triple-negative breast cancer.
  • TNBC is an aggressive type of breast cancer, accounting for approximately 15% of all breast cancers.
  • In addition to multiple ongoing studies of SG in triple-negative breast cancer, it is being developed as an investigational treatment for metastatic urothelial cancer, hormone receptor-positive/HER 2-negative metastatic breast cancer, and metastatic non-small cell lung cancer, either as a monotherapy or in combination with other agents.

Study Published in British Journal of Cancer Shows High Sensitivity and Specificity of Tethis' Liquid Biopsy Platform in Early Stage Breast Cancer and The Identification of Circulating Tumor Cells Clusters for the First Time in Non-Metastatic Patients

Retrieved on: 
Thursday, March 25, 2021
Clinical medicine, Medicine, Medical specialties, Oncology, Anatomical pathology, Circulating tumor cell, Biopsy, Metástasis, Liquid biopsy, Breast cancer

The full paper can be accessed at https://www.nature.com/articles/s41416-021-01327-8.

Key Points: 
  • The full paper can be accessed at https://www.nature.com/articles/s41416-021-01327-8.
  • Moreover, for the first time, it was possible to identify CTC clusters in 5 out of 28 patients with early breast cancer, so far only described in metastatic settings.
  • Tethis S.p.A is based in Milan, Italy, and is developing a novel workflow to bring liquid biopsy in the clinical practice for the precise management of cancer.
  • The company's proprietary nanocoated slides combined with the automated pre-analytical instrument allow to identify and characterize rare cells in blood, like circulating tumor cells, with unprecedented sensitivity, also in early stage settings.

Study Published in British Journal of Cancer Shows High Sensitivity and Specificity of Tethis' Liquid Biopsy Platform in Early Stage Breast Cancer and The Identification of Circulating Tumor Cells Clusters for the First Time in Non-Metastatic Patients

Retrieved on: 
Thursday, March 25, 2021
Clinical medicine, Medicine, Medical specialties, Oncology, Anatomical pathology, Circulating tumor cell, Biopsy, Metástasis, Liquid biopsy, Breast cancer

The full paper can be accessed at https://www.nature.com/articles/s41416-021-01327-8.

Key Points: 
  • The full paper can be accessed at https://www.nature.com/articles/s41416-021-01327-8.
  • Moreover, for the first time, it was possible to identify CTC clusters in 5 out of 28 patients with early breast cancer, so far only described in metastatic settings.
  • Tethis S.p.A is based in Milan, Italy, and is developing a novel workflow to bring liquid biopsy in the clinical practice for the precise management of cancer.
  • The company's proprietary nanocoated slides combined with the automated pre-analytical instrument allow to identify and characterize rare cells in blood, like circulating tumor cells, with unprecedented sensitivity, also in early stage settings.

Delcath Systems Schedules Conference Call to Report 2020 Fourth Quarter Financial Results

Retrieved on: 
Wednesday, March 24, 2021
Medical specialties, Oncology, Medicine, Health, Delcath Systems, Interventional oncology, Metástasis

NEW YORK, March 24, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq:DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on March 31, 2021 at 8:00 AM Eastern Time to discuss results for its fourth quarter ended December 31, 2020.

Key Points: 
  • NEW YORK, March 24, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq:DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on March 31, 2021 at 8:00 AM Eastern Time to discuss results for its fourth quarter ended December 31, 2020.
  • To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.
  • The call will also be available over the Internet and accessible at: https://www.webcaster4.com/Webcast/Page/2475/40544
    Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers.
  • HEPZATO KIT has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S.

Quantgene and CureMatch Announce Strategic Partnership To Help Cancer Patients Find the Best Precision Treatment

Retrieved on: 
Wednesday, March 24, 2021
Medicine, Clinical medicine, Medical specialties, Oncology, Biopsy, Cancer screening, Liquid biopsy, Metástasis, Cancer, Circulating tumor DNA, Oncogenomics

Quantgene Liquid uses blood samples of cancer patients to help provide a systemic understanding of the mutational profiles of a tumor, also known as a "Liquid Biopsy".

Key Points: 
  • Quantgene Liquid uses blood samples of cancer patients to help provide a systemic understanding of the mutational profiles of a tumor, also known as a "Liquid Biopsy".
  • By profiling cell-free DNA fragments in the blood, Quantgene Liquid allows better insights into both primary and metastatic tumors.
  • Cancer patients can get results in as little as 3 weeks from a blood draw, to a Quantgene test result1 to a CureMatch report that informs their precision treatment.
  • Jo Bhakdi, founder and CEO of Quantgene said of the partnership: "Deep Genomics and AI can be a game-changer for cancer patients.

Processa Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter Results and Provide Drug Development Update on March 25 at 5:30 p.m. ET

Retrieved on: 
Monday, March 22, 2021
Digestive diseases, Medical specialties, Clinical medicine, Communication, Forward-looking statement, Necrobiosis, Cancer, Metástasis, Breast cancer, Colorectal cancer, Gastroparesis

The Company uses these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently.

Key Points: 
  • The Company uses these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently.
  • Active clinical pipeline programs include: PCS6422 (metastatic colorectal cancer and breast cancer), PCS499 (ulcerative necrobiosis lipoidica) and PCS12852 (GI motility/gastroparesis).
  • The statements in this press release that are not purely historical are forward-looking statements which involve risks and uncertainties.
  • Actual future performance outcomes and results may differ materially from those expressed in forward-looking statements.

Avalon GloboCare Expands Co-Development Program with MIT to Combat Cancer Metastasis

Retrieved on: 
Monday, March 22, 2021
Cancer, Oncology, Cancer pathology, Metástasis, CRISPR gene editing, Shuguang Zhang

Metastasisthe spreading of cancer cells from the initial tumor site to surrounding tissues and distant organsis responsible for the vast majority of cancer deaths.

Key Points: 
  • Metastasisthe spreading of cancer cells from the initial tumor site to surrounding tissues and distant organsis responsible for the vast majority of cancer deaths.
  • In an ongoing co-development research program, Avalon and the laboratory of Dr. Shuguang Zhang at MITs Media Lab have developed a novel approach to potentially block the signals that cancer cells require to metastasize in order to prevent cancer spread and death.
  • Avalon and MIT researchers are also working on a second approachcombining the QTY technology with the CRISPR-Cas9 gene editing system to re-program cell types that typically stimulate nearby cancer cells to spread, thereby deterring cancer metastasis.
  • This new endeavor builds on our collaboration with MIT using the QTY code technology to develop innovative therapies for cancer metastasis, stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon.

Catenin Beta 1 Pipeline Review, H2 2020 - ResearchAndMarkets.com

Retrieved on: 
Monday, March 22, 2021
Pharmaceutical, Health, Clinical trials, Cancer pathology, Oncology, Amyloidosis, PRNP, Metástasis, Medicine, Clinical medicine, Health

Oct 21, 2019: Propanc Biopharma illustrates novel mode of action of PRP, suppressing EMT Pathways and Metastasis in Cancer Patients

Key Points: 

Oct 21, 2019: Propanc Biopharma illustrates novel mode of action of PRP, suppressing EMT Pathways and Metastasis in Cancer Patients
Mar 13, 2019: Propanc Biopharma receives notice of allowance for additional claims from foundation patent in the U.S.

Processa Announces Sites Selected for Phase 2B Clinical Trial to Treat Patients with Ulcerated Necrobiosis Lipoidica

Retrieved on: 
Wednesday, March 17, 2021
Medical specialties, Digestive diseases, Clinical medicine, Diabetes, Necrobiosis lipoidica, Necrobiosis, Cancer, Breast cancer, Gastroparesis, Ulcer, Metástasis

A summary of the study and a listing of the sites selected can be found at https://clinicaltrials.gov using the NCT number of NCT04800562.

Key Points: 
  • A summary of the study and a listing of the sites selected can be found at https://clinicaltrials.gov using the NCT number of NCT04800562.
  • Necrobiosis Lipoidica (NL) is a rare, painful condition affecting the skin and tissue under the skin typically on the lower extremities.
  • We have selected 5 US sites to evaluate this ground-breaking new treatment for ulcerative necrobiosis lipoidica and we expect to add a few more sites in the next few months including sites outside the U.S.
  • Active clinical pipeline programs include: PCS6422 (metastatic colorectal cancer and breast cancer), PCS499 (ulcerative necrobiosis lipoidica) and PCS12852 (GI motility/gastroparesis).

CNS Pharmaceuticals to Participate in Inaugural Emerging Growth Virtual Conference

Retrieved on: 
Monday, March 15, 2021
Oncology, Cancer pathology, Metástasis

HOUSTON, March 15, 2021 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that John Climaco, CEO of CNS Pharmaceuticals will present at the inaugural Emerging Growth Virtual Conference presented by M Vest LLC and Maxim Group LLC.

Key Points: 
  • HOUSTON, March 15, 2021 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that John Climaco, CEO of CNS Pharmaceuticals will present at the inaugural Emerging Growth Virtual Conference presented by M Vest LLC and Maxim Group LLC.
  • Interested parties are invited to attend the virtual conference and access exclusive content by becoming an M-Vest member and registering HERE.
  • To learn more about the event, please visit the conference website: Emerging Growth Virtual Conference .
  • CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system.